Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Non-Invasive Screening for Embryo Chromosome Abnormalities Using Growth Patterns and Culture Fluid Analysis (PEARL 1)

10. november 2026 opdateret af: Fakih IVF Fertility Center

Prediction of Embryo Aneuploidy Using Non-invasive Morphokinetics and Culture Media Readouts

For Couples undergoing in vitro fertilization (IVF), one of the most important decisions is choosing which embryo has the best chance of leading to a healthy pregnancy. Today, this often relies on a biopsy, where a few cells are removed from the embryo for genetic testing (PGT-A). This technique has shown high accuracy; however, this test is invasive, adds cost, and involves handling the embryo directly.

The Prediction of Embryo Aneuploidy using Non-invasive Morphokinetics and Culture Media Readouts (PEARL) Trial is testing a non-invasive alternative that combines two approaches. The first; time-lapse imaging using a camera-equipped incubator to continuously record how an embryo divides and grows, without ever removing it from its stable environment. The second; spent culture media testing by analyzing the fluid that the embryo grows in for biological signals (DNA fragments, microRNA, proteins, and metabolic byproducts) which the embryo releases as it develops.

By studying these two sources of information together, alongside each embryo's actual genetic result from standard PGT-A testing, we aim to find out whether imaging and fluid analysis, combined, can reliably predict whether an embryo is chromosomally normal (euploid) or abnormal (aneuploid) without needing a biopsy.

Taking part does not change a couple's standard IVF treatment. Embryos are cultured and tested exactly as they normally would be; the only difference is that imaging data and a small sample of fluid that would otherwise be thrown away are collected for research analysis. All embryo selection and transfer decisions continue to be based on the clinic's usual standard of care.

If successful, this approach could make embryo assessment safer, faster, and more affordable reducing the need for invasive testing in IVF, in Abu Dhabi and internationally.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Time-lapse imaging (TLI) enables continuous, non-invasive assessment of embryo development. Early cleavage timings (t2, t3), cell cycle durations (cc2, cc3), and synchrony measures (s2, s3) have been associated with developmental competence, while later morphokinetic events; compaction and blastocyst expansion, appear particularly informative for blastocyst quality and may carry signals related to chromosomal status.

In parallel, spent embryo culture media (SECM) studies report that cell-free DNA (cfDNA) fragments, microRNA expression patterns, metabolic profiles, and specific secreted proteins differ between embryos with divergent developmental and genetic outcomes, suggesting SECM as a complementary, non-invasive biomarker source.

However, methodological variability across studies; including inconsistent sample collection timing, inadequate contamination control, and heterogeneous assay platforms, limits reproducibility and has constrained clinical translation. Critically, no adequately powered, prospective study has yet integrated detailed morphokinetic profiling with multi-omic SECM assessment and validated the combined approach against preimplantation genetic testing for aneuploidy (PGT-A) as a reference standard.

The PEARL Trial addresses this gap through a large, prospective, standardized dataset combining TLI-derived morphokinetic parameters with multi-omic SECM analysis (cfDNA, microRNA, metabolomic, and proteomic markers), collected under controlled conditions to minimize pre-analytical variability. All embryos will undergo routine PGT-A per standard clinical protocol, providing ground-truth ploidy status against which combined predictive models will be evaluated.

The primary objective is to determine the correlation between integrated morphokinetic/SECM signatures and embryo ploidy, and to assess the predictive performance of a combined non-invasive model relative to PGT-A. Embryo culture and clinical decision-making will follow standard institutional protocols throughout, with TLI and SECM sampling embedded within existing laboratory workflows to avoid any deviation from standard-of-care embryo handling.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

200

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 40 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Participants will be selected from IVF patients attending the FAKIH IVF clinic in Abu Dhabi.

Beskrivelse

Inclusion Criteria:

  1. Women aged 21-40 years undergoing IVF/ICSI cycles at Fakih IVF Centre.
  2. Embryos cultured in validated timelapse incubators to the blastocyst stage or until developmental arrest.
  3. Availability of spent embryo culture media (SECM) samples and preimplantation genetic testing for aneuploidy (PGT-A) results for blastocysts

Exclusion Criteria:

  1. Known parental chromosomal abnormalities identified prior to the IVF cycle.
  2. Missing or contaminated SECM samples for analysis

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Aneuploid Embryos

Embryo culture spent media collected and frozen, then for embryos which are identified as aneuploid by PGT-A, their frozen spent media and morphokinetics will be analyzed.

This is an observation cohort. There are no interventions in this study.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
miRNA expression profiles
Tidsramme: Day 6 or 7 of embryo culture.

miRNA expression profiles of spent media from embryo culture.

Day 6 or 7 of embryo culture.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Correlation between spent media analysis and morphokinetics
Tidsramme: Day 6 or 7 of embryo culture.

Correlation between spent media analysis and morphokinetics in PGT-A confirmed Aneuploid embryos. Spent media harvested within 24 hours of embryo removal from culture media.

Day 6 or 7 of embryo culture.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Lamiya Mohiyiddeen, MD, FRCOG, Fakih IVF Abu Dhabi
  • Ledende efterforsker: Dr. Yasmin Sajjad, MD, FRCOG, DOWH, Fakih IVF Abu Dhabi
  • Ledende efterforsker: Dr. Michael Fakih, PhD, Fakih IVF Abu Dhabi

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

25. november 2026

Primær færdiggørelse (Anslået)

25. november 2027

Studieafslutning (Anslået)

30. december 2027

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • FAKIH-2025-12
  • DOH/ADHRTC/2026/500 (Anden identifikator: Department of Health Abu Dhabi)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .